A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing
Employees: 1001-5000
Founded date: 2021
Mentions in press and media 10
| Date | Title | Description |
| 21.08.2024 | WuXi XDC: A Surge in Growth and Ambition in the Bioconjugate Market | WuXi XDC Cayman Inc. is riding a wave of success. The company, a titan in the Contract Research, Development, and Manufacturing Organization (CRDMO) sector, has unveiled impressive financial results for the first half of 2024. With a revenu... |
| 20.08.2024 | WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth | Revenue surged by 67.6% YoY to RMB 1,665 million Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023. Net profit increased by 175.5% to RMB 488 million,... |
| 20.08.2024 | WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth | Revenue surged by 67.6% YoY to RMB 1,665 million Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023. Net profit increased by 175.5% to RMB 488 million,... |
| 25.03.2024 | WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones | Revenue reached RMB 2,124 million, an increase of 114% compared with Year 2022 Adjusted net profit reached RMB 412 million, an increase of 112% compared with Year 2022 Total number of integrated projects increased to 143 50 new integrated p... |
| 31.01.2024 | WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development | SHANGHAI, Jan. 31, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clin... |
| 24.01.2024 | WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs) | SHANGHAI and INCHEON, South Korea, Jan. 24, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltr... |
| 17.11.2023 | WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange | HONG KONG, Nov. 17, 2023 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization ("CRDMO") focused... |
| 20.10.2023 | WuXi XDC Named Best CDMO Winner at 2023 World ADC Awards | SHANGHAI, Oct. 20, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract, Research, Development, and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, announced it has been named the winner of the &... |
| 18.10.2023 | WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong | Hong Kong Science and Technology Parks Corporation (HKSTPC) and WuXi XDC signed a cooperation framework agreement to jointly promote the establishment of a contract research, development and manufacturing organization(CRDMO) value chain in ... |
| 20.09.2023 | WuXi XDC Launches New Commercial Manufacturing Facilities | New commercial facilities offer one-stop manufacturing services for antibody intermediates, bioconjugate drug substance and drug product Doubled capacity provides greater support to the rapidly growing global bioconjugate industry WUXI, Chi... |